Kinetic control of reactions of a sterically hindered platinum picoline anticancer complex with guanosine 5′-monophosphate and glutathione

Abstract

Kinetic studies (296 K, 0.1 M NaClO₄, pH 6–7) of reactions of the anticancer complex cis-[PtCl₂(NH₃)(2-pic)] 1 (AMD473) (2-pic = 2-picoline) with guanosine 5′-monophosphate (5′-GMP) and the tripeptide glutathione (GSH) using 2D [¹H, ¹⁵N] HSQC NMR spectroscopy have been made, and compared to reactions of the isomeric complex cis-[PtCl₂(NH₃)(3-pic)] 2. Reactions with 5′-GMP followed two pathways with either hydrolysis trans to NH₃ or picoline as the first step, with subsequent formation of Cl/GMP and H₂O/GMP intermediates, and cis-[Pt(¹⁵NH₃)(pic)(5′-GMP-N7 )₂]²⁺ as the final product. Eight rate constants were determined for each starting platinum complex 1 and 2. The rates of ligand substitution (Cl^– by H₂O and H₂O by 5′-GMP) cis to 2-picoline were 2–12 times slower than the same ligand substitution cis to 3-picoline. This was also the case for ligand substitution trans to 2-picoline (2–3 times slower), except that when 5′-GMP was present as the cis ligand (second stage of substitution) the rate of substitution was enhanced for the 2-picoline complex. Slow rotation about the Pt–N picoline bond (0.62 s^–1) and fast rotation about Pt-N7 GMP bonds on the NMR timescale were observed at 296 K for the bis(GMP) adduct of complex 1, while these were both fast for the analogous adduct of complex 2. Reactions of GSH with 1 were ca. 3 times slower than those with 2, and appeared to proceed via aquated intermediates with initial substitution trans to 2-picoline for 1 and trans to NH₃ for 2, but no kinetic analyses were attempted due to the complexity of the reactions. Both mono- and bis-GMP adducts were observed during competitive reactions of GSH and 5′-GMP with complex 1 (molar ratio: 2∶2∶1) at pH 7, 296 K. These features of the chemistry of 1 may play an important role in its altered spectrum of biological activity compared to cisplatin.

References

1. J. Reedijk, Chem. Commun., 1996, 801.
2. F. I. Raynaud, F. E. Boxall, P. M. Goddard, M. Valenti, M. Jones, B. A. Murrer, M. Abrams and L. R. Kelland, Clin. Cancer Res., 1997, 3, 2063.
3. J. Holford, S. Y. Sharp, B. A. Murrer, M. Abrams and L. R. Kelland, Br. J. Cancer, 1998, 77, 366.
4. J. Holford, F. Raynaud, B. A. Murrer, K. Grimaldi, J. A. Hartley, M. Abrams and L. R. Kelland, Anti-Cancer Drug Design, 1998, 13, 1.
5. Y. Chen, Z. J. Guo, S. Parsons and P. J. Sadler, Chem. Eur. J., 1998, 4, 672.
6. S. E. Miller and D. A. House, Inorg. Chim. Acta, 1989, 161, 131.
7. F. Raynaud, F. Boxall, P. Goddard, M. Valenti, M. Jones, B. Murrer, C. Giandomenico and L. Kelland, Proc. 88th Annual Meeting American Assoc. Cancer Res., San Diego, CA, 12–16 April 1997, vol. 38, no. 2085, p. 311.
8. Y. Zou, B. Van Houten and N. Farrell, Biochemistry, 1993, 32, 9632.
9. R. N. Bose, S. Moghaddas, E. L. Weaver and E. H. Cox, Inorg. Chem., 1995, 34, 5878.
10. J. Reedijk, in Handbook of Metal—Ligand Interactions in Biological Fluids, ed. G. Berthon, Marcel Dekker, New York, 1995, vol. 2, p. 967.
11. T. Ishikawa, C. D. Wright and H. Ishizuka, J. Biol. Chem., 1994, 29085.
12. S. J. S. Kerrison and P. J. Sadler, J. Chem. Soc., Chem. Commun., 1977, 861.
13. S. J. Barton, K. J. Barnham, A. Habtemariam, P. J. Sadler and R. E. Sue, Inorg. Chim. Acta, 1998, 273, 8.
14. M. Piotto, V. Saudek and V. Sklenar, J. Biomol. NMR, 1992, 2, 661.
15. J. Stonehouse, G. L. Shaw, J. Keeler and E. D. Laue, J. Magn. Reson., Ser. A, 1994, 107, 178.
16. E. W. Abel, T. P. J. Coston, K. G. Orrell, V. Sik and D. Stephenson, J. Magn. Reson., 1986, 70, 34.
17. S. J. Berners-Price and P. J. Sadler, Coord. Chem. Rev., 1996, 151, 1.
18. H. Friebolin, Basic One- and Two-Dimensional NMR Spectroscopy, VCH, Weinheim, 1991.
19. G. Pettit and L. D. Pettit, IUPAC Stability Constants Database, IUPAC and Academic Software, Otley, 1993.
20. F. Basolo, J. Chatt, H. B. Gray, R. G. Pearson and B. L. Shaw, J. Chem. Soc., 1961, 2207.
21. D. F. Shriver, P. W. Atkins and C. H. Langford, Inorganic Chemistry, 2nd edn., Oxford University Press, 1994, p. 627.
22. R. Romeo, D. Minniti and M. Trozzi, Inorg. Chem., 1976, 15, 1134.
23. S. S. Eapen, M. Green and I. M. Ismail, J. Inorg. Biochem., 1985, 24, 233.
24. K. J. Barnham, S. J. Berners-Price, T. A. Frenkiel, U. Frey and P. J. Sadler, Angew. Chem., 1995, 34, 1874.
25. S. J. Berners-Price, K. J. Barnham, U. Frey and P. J. Sadler, Chem. Eur. J., 1996, 2, 1283.
26. D. Kiser, F. P. Intini, Y. Xu, G. Natile and L. G. Marzilli, Inorg. Chem., 1994, 33, 4149.
27. B. Lippert, Prog. Inorg. Chem., 1989, 37, 1.
28. M. D. Reily and L. G. Marzilli, J. Am. Chem. Soc., 1986, 108, 6785.
29. Y. Xu, G. Natile, F. P. Intini and L. G. Marzilli, J. Am. Chem. Soc., 1990, 112, 8177.
30. R. E. Cramer and P. L. Dahlstrom, Inorg. Chem., 1985, 24, 3420.
31. S. J. Berners-Price, U. Frey, J. D. Ranford and P. J. Sadler, J. Am. Chem. Soc., 1993, 115, 8649.
32. K. Inagaki, F. J. Dijt, E. L. M. Lempers and J. Reedijk, Inorg. Chem., 1988, 27, 382.
33. A. T. M. Marcelis, J. L. Van Der Veer, J. C. M. Zwetsoot and J. Reedijk, Inorg. Chim. Acta, 1983, 78, 195.
34. K. Okamoto, V. Behnam, M. T. Phan Viet, M. Polissiou, J. Y. Gauthier, S. Hanessian and T. Theophanides, Inorg. Chim. Acta, 1986, 123, L3.
35. J. F. Hartwig and S. J. Lippard, J. Am. Chem. Soc., 1992, 114, 5646.
36. A. J. Repta and D. F. Long, in Cisplatin Current Status and New Developments, eds. A. W. Prestayko, S. T. Crooke and S. K. Carter, Academic Press, New York, 1980, p. 285.
37. M. I. Djuran, E. L. M. Lempers and J. Reedijk, Inorg. Chem., 1991, 30, 2648.
38. B. J. Corden, Inorg. Chim. Acta, 1987, 137, 125.
39. T. G. Appleton, J. W. Connor, J. R. Hall and P. D. Prenzler, Inorg. Chem., 1989, 28, 2030.
40. K. J. Barnham, M. I. Djuran, P. del S. Murdoch, J. D. Ranford and P. J. Sadler, Inorg. Chem., 1996, 35, 1065.
41. B. Odenheimer and W. Wolf, Inorg. Chim. Acta, 1982, 66, L41.